GRI Bio Inc. is a forward-thinking biotechnology company specializing in microbiome technology to deliver advanced therapeutics in immunology and oncology. By prioritizing the treatment of root causes rather than just symptom relief, GRI Bio aims to address significant unmet medical needs with its innovative therapies. The company boasts a robust pipeline of product candidates and has established strategic collaborations to enhance its research capabilities. Positioned at the forefront of the burgeoning microbiome therapeutics market, GRI Bio is committed to improving patient outcomes and has the potential to significantly advance healthcare solutions.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-10.93M |
| Operating Margin | 0.00% |
| Return on Equity | -185.70% |
| Return on Assets | -88.80% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $6.65 |
| Price-to-Book | 0.31 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $1.77M |
| Float | $1.77M |
| % Insiders | 0.46% |
| % Institutions | 2.80% |
Volatility is currently contracting
Designation highlights significant regulatory milestone and provides a potential pathway to seven years of U.S. market exclusivity
Live webcast fireside chat with Marc Hertz, PhD, Chief Executive Officer, on Wednesday, May 20, 2026 Register for the event here LA JOLLA, CA, May 18, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that Marc Hertz, PhD, Chief Executive Officer of GRI Bio, will participate in a fireside chat at A.G.P.'s Annual Healthcare Company Showcase being held virtually on Wednesday, May 20, 2026.
Phase 2a data show zero cough and 60% lower treatment-related diarrhea than placebo despite higher nintedanib use in the active arm – suggesting GRI-0621 may mitigate nintedanib-related GI-toxicities when used in combination
Issued claims further strengthen global intellectual property portfolio supporting immune cell modulation platform and expand strategic presence in a high-growth international market
